[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507823":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":48,"centralContacts":52,"locations":59,"responsibleParty":79,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":57,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":57,"enrollmentInfo":95,"targetDuration":57,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":57,"overallStatus":61,"whyStopped":57,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A ([89Zr]DFO-YS5, single scan","EXPERIMENTAL","Participants receive \\[89Zr\\]DFO-YS5 IV and undergo a single PET\u002FCT or PET\u002FMRI scan 5-7 days post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET\u002FCT or PET\u002FMRI scan within 28 days prior to day 1",[13,14,15,16],"Drug: Zirconium Zr 89-DFO-YS5","Procedure: Positron Emission Tomography \u002F Computed Tomography (PET\u002FCT)","Procedure: Positron Emission Tomography \u002F Magnetic Resonance Imaging (PET\u002FMRI)","Other: Fludeoxyglucose F-18",{"label":18,"type":10,"description":19,"interventionNames":20},"Cohort B ([89Zr]DFO-YS5, multiple scans","Participants receive \\[89Zr\\]DFO-YS5 IV and undergo four PET\u002FCT or PET\u002FMRI scans on days 1, 2, 3-4, and 5-7 post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET\u002FCT or PET\u002FMRI scan within 28 days prior to day 1",[13,14,15,16],[22,30,37,43],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Zirconium Zr 89-DFO-YS5","Given IV",[9,18],[28,29],"(89)Zr-DFO-YS5","89Zr DFO-YS5",{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"PROCEDURE","Positron Emission Tomography \u002F Computed Tomography (PET\u002FCT)","Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image",[9,18],[36],"PET\u002FCT",{"type":31,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Positron Emission Tomography \u002F Magnetic Resonance Imaging (PET\u002FMRI)","Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.",[9,18],[42],"PET\u002FMRI",{"type":6,"name":44,"description":25,"armGroupLabels":45,"otherNames":46},"Fludeoxyglucose F-18",[9,18],[47],"Fludeoxyglucose (18F)",[49],{"name":50,"affiliation":5,"role":51},"Robert Flavell, MD, PhD","PRINCIPAL_INVESTIGATOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":57,"email":58},"Maya Aslam","CONTACT","(415) 514-8987",null,"Maya.Aslam@ucsf.edu",[60],{"facility":5,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"RECRUITING","San Francisco","California","94143","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-122.41942,37.77493,{"lat":71,"lon":70},[74,75,78],{"name":54,"role":55,"phone":56,"phoneExt":57,"email":58},{"name":57,"role":55,"phone":76,"phoneExt":57,"email":77},"877-827-3222","cancertrials@ucsf.edu",{"name":50,"role":51,"phone":57,"phoneExt":57,"email":57},{"type":80,"investigatorFullName":50,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":57,"oldOrganization":57},"SPONSOR_INVESTIGATOR","Principal Investigator",[83],{"name":84,"class":85},"National Cancer Institute (NCI)","NIH","100507823","phase-1-imaging-study-of-89zrdfo-ys5-for-detecting-cd46-positive-malignancy-in-multiple-myeloma-100507823",false,"NCT05892393","Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma","Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria\n* At least one positive myelomatous lesion found on 18F-FDG PET\u002FCT or PET\u002FMRI. A positive lesion is defined as uptake greater than liver on FDG PET, based on the Italian myeloma criteria for PET use (IMPeTUs) criteria\n* Age \\>= 18 years\n* Total bilirubin =\\\u003C 1.5 X institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) =\\\u003C 3 X ULN\n* Alanine aminotransferase (ALT) =\\\u003C 3 X ULN\n* Creatinine clearance \\>= 30 mL\u002Fmin, calculated using the Cockcroft-Gault equation or serum creatinine \\\u003C= 1.5x the institutional upper limit of normal.\n* Ability to understand a written informed consent document, and the willingness to sign it\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the principal investigator, would impair the participants' ability to comply with study procedures or interfere with the safety of the investigational regimen\n* Individuals who are pregnant or breastfeeding\u002Fchestfeeding.\n* \\- Breast-feeding\u002Fchest-feeding should be discontinued before administration of \\[89ZR\\]DFO-YS5.\n* Females of childbearing potential must have a negative urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours prior to administration of \\[89ZR\\]-DFO-YS5.\n* \\- If the urine pregnancy test is positive or equivocal, a confirmatory serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive.\n* \\- A female is considered to be of childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), unless it is documented that the individual meets either of the following two criteria: (1) has reached a postmenopausal state ( \\>= 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries).\n* Individuals who are pregnant or breastfeeding\u002Fchestfeeding are excluded because there is an unknown but potential risk for adverse effects in the unborn\u002Fnursing child secondary to treatment of the study participant with \\[89ZR\\]-DFO-YS5","ALL","18 Years",{"count":96,"type":97},20,"ESTIMATED","INTERVENTIONAL",[100],"PHASE1","This phase I trial tests the safety of \\[89Zr\\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \\[89Zr\\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \\[89Zr\\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \\[89Zr\\]DFO-YS5 PET scans may improve detection of multiple myeloma.",[103,104],"Multiple Myeloma","Plasma Cell Myeloma","2026-06-11",{"date":107,"type":108},"2026-06-15","ACTUAL",{"date":110,"type":108},"2023-06-16",{"date":112,"type":97},"2026-09-01",{"name":50,"class":6},1]